Background: Pre-planned futility analyses are commonly used in oncology studies. The LUME-Lung 2 study (NCT00806819; 1199.14) was stopped early based on a pre-planned, non-binding futility analysis of investigator-assessed progression-free survival (PFS), although subsequent analysis showed that the primary endpoint of improvement in centrally reviewed PFS was met. Retrospective analyses were conducted to understand the discrepancy between interim futility and final analyses.
Introduction
Interim monitoring of clinical trials allows for a clinical trial to be stopped early if the final results of the study become 'obvious' before the trial is due to end. Independent Data Monitoring Committees (DMCs) are recommended to perform interim clinical trial monitoring during the conduct of controlled trials and to compare rates of mortality or major morbidity for early evidence of treatment benefit or harm [1, 2] . Interim analyses for lack of benefit, or futility, use the results from patients recruited up to a specific time point to make statistical assumptions about the final outcome of the study. The concept of futility analyses was originally proposed in the early 1980s [3, 4] , and futility analyses are now routinely used in phase III oncology clinical trials. In fact, there have been calls for futility analyses to be included in publicly funded trials whenever possible as they are thought to increase efficiency, prevent unnecessary exposure of patients to ineffective treatments and decrease costs [5] . Despite these advantages, statistical futility methods are not infallible and the inclusion of these analyses in clinical trials does not remove the need for careful clinical and ethical judgement as a trial progresses. Here, we discuss some of the potential pitfalls of futility analyses and report one study that serves as an example of how futility needs to be handled with care.
There are several statistical methods for the assessment of futility in clinical trials [6] . One commonly used method calculates the conditional power-the probability of the new treatment being better than the control treatment at the end of the study based on the interim results and the efficacy assumptions of the trial-and, if the probability of the trial meeting the pre-specified efficacy criteria is too small, the study is stopped for futility [7] . One potential disadvantage of stopping clinical trials early for futility is that a final analysis may demonstrate a positive result or a trend towards a positive result. Consequently, a potentially valuable treatment is abandoned or a subsequent trial must be planned and executed.
Studies of non-small cell lung cancer (NSCLC) in both the first-line [8] [9] [10] [11] [12] [13] [14] [15] [16] and second-line [17, 18] treatment settings have been stopped early because futility criteria were met. None of these trials showed a statistically significant treatment effect when the results from all enrolled patients were analysed and reported, indicating that the futility predictions were accurate. To our knowledge, no trials have previously been closed based on interim analysis for futility and later shown to have significant positive findings at the final analysis.
Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptors 1-3, platelet-derived growth factor receptor-a and -b and fibroblast growth factor receptors 1-3, with inhibitory activity against other kinases, including Flt-3 [19] . Nintedanib was approved in the European Union and other countries for use in combination with docetaxel for the treatment of locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy based on the results of the LUME-Lung 1 study [20] . In this phase III trial (NCT00805194; 1199.13), the addition of nintedanib to docetaxel was shown to significantly improve both progression-free survival (PFS) by independent central review in all patients and overall survival (OS) in patients with adenocarcinoma histology [median: 12.6 versus 10.3 months, hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.70-0.99, P ¼ 0.0359] [20] .
Concurrent to the LUME-Lung 1 study, another phase III trial, LUME-Lung 2 (NCT00806819; 1199.14), investigated the efficacy and safety of nintedanib in combination with pemetrexed versus placebo-pemetrexed for the treatment of patients with advanced or recurrent non-squamous NSCLC who had relapsed or failed one prior line of chemotherapy [21] . Based on the results of a pre-planned, non-binding futility analysis of investigatorassessed PFS, conducted by an independent DMC, recruitment was halted early because the likelihood of the study meeting the primary endpoint was low and it met the protocol-established criterion for early termination. At the time that the study was halted, 713 of the planned 1300 patients had been randomized to treatment; no safety concerns were identified. Patients who were still on study treatment at this time could continue in the trial and were followed up for safety and efficacy, according to the trial protocol, until the final analysis of data. This analysis showed that the primary endpoint of improvement in centrally reviewed PFS was met; treatment with nintedanib-pemetrexed resulted in a statistically significant prolongation of centrally reviewed PFS compared with placebo-pemetrexed [21] . Here, we report details of the pre-planned futility analysis from LUME-Lung 2, as well as retrospective analysis of the futility calculations, to understand better the discrepancy between the interim futility and final analyses.
Patients and methods
Study design LUME-Lung 2 was a global, phase III, multicentre, randomized, double-blind, placebo-controlled trial, in which patients with advanced non-squamous NSCLC previously treated with chemotherapy were randomized to receive nintedanib 200 mg twice daily plus intravenous pemetrexed 500 mg/m 2 or placebo-pemetrexed (same dose) in 21-day cycles until progression or unacceptable toxicity. Full details of inclusion and exclusion criteria have been presented elsewhere; all patients provided informed consent to participate [21] .
The primary study endpoint was PFS [according to modified Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 criteria [22] ; further details of the modified criteria are given in the Appendix], as assessed by independent central review. Investigator-assessed PFS was a secondary endpoint and was used for futility analyses, as independent, centrally reviewed response data were available only for patients who had experienced progressive disease. OS was a key secondary endpoint. The study planned to recruit 1300 patients based on the assumption that a total of 713 PFS events were required for the primary analysis to provide 90% power to detect a 27.5% increase in median PFS with nintedanib-pemetrexed versus placebo-pemetrexed (HR 0.78). For the final analyses of OS, 1151 deaths would have 80% power at a two-sided a-level of 0.05 to detect an 18% improvement in OS (HR 0.85).
Median follow-up time in each treatment arm was calculated using the Kaplan-Meier estimator method proposed by Schemper and Smith [23] , with loss of follow-up treated as an event and death treated as a censored observation.
Pre-planned futility analysis
The LUME-Lung 2 trial protocol specified that a pre-planned, non-binding futility analysis was carried out by the DMC after 50% of the events for the primary PFS analysis had been observed (356 events). The threshold for futility was set in the DMC charter at a conditional power of 20%; a value below this would indicate that the trial was likely to be futile (see Appendix for further details).
Retrospective analysis of the conditional and predictive powers
Analysis of the primary endpoint, independently assessed PFS, was conducted after 498 PFS events following database lock on 9 July 2012. At this time, retrospective analyses of the conditional and predictive powers of the study, and corresponding HR estimations, were carried out for investigator-assessed and centrally reviewed PFS data. Conditional and predictive powers were calculated according to the pre-planned futility analysis [24] and thus in the same manner as was done in the trial.
For the retrospective assessment, conditional and predictive powers and HRs were investigated over time after 10%, 20%, 30%, 40%, 50%, 60% and 70% of events for the primary PFS analysis (713 PFS events) had occurred. In addition, conditional and predictive powers for the trial were also recalculated at the time of the pre-planned futility analysis (48% of PFS events), as the database in the retrospective analysis was more mature than that used by the DMC.
Retrospective analysis using alternative futility rules
The effect of using group sequential methods, such as Hwang et al. [25] , for futility assessment was explored in a retrospective analysis; all calculations and simulations were done using ADDPLAN V R adaptive trial design software [26] .
Results

Pre-planned futility analysis
The pre-planned futility analysis was conducted by the independent DMC using investigator-assessed PFS carried out on a database snapshot as of 14 March 2011. Forty-eight per cent (n ¼ 346) of the events required for the primary PFS analysis had occurred and, at this time, the conditional power was 10.3% and the predictive power was 18.5%. As the conditional power was lower than the predefined threshold for futility, the analysis indicated that the study was unlikely to reach the predefined efficacy criteria. The DMC recommended halting further recruitment. Although the futility analysis was non-binding and the sponsor could have overruled the DMC, this option was rejected by the sponsor after due consideration and, therefore, recruitment into this trial was halted on 18 June 2011. The DMC also recommended exploring which subgroups might benefit from nintedanib treatment as there were no safety issues identified. Median treatment follow-up was similar between treatment groups at the time of this analysis and did not differ in retrospective analyses (Table 1) .
Retrospective analysis of the conditional and predictive powers
Investigator-assessed PFS. The conditional and predictive powers calculated for investigator-assessed PFS for varying numbers of PFS events are shown in Figure 1A . Retrospective analysis showed that the conditional and predictive powers fluctuated over time, but remained on average 20% above the predefined futility criteria throughout the study. Only at the time of the futility analysis did the power drop by a notable amount. The HRs and 95% CIs for investigator-assessed PFS for varying numbers of PFS events are shown in Figure 1B . At the time of the futility analysis, the HR for investigator-assessed PFS was 0.92 (95% CI 0.74-1.14), confirming the DMC recommendation to stop the trial for futility.
Centrally reviewed PFS. The retrospective conditional and predictive powers for centrally reviewed PFS at varying numbers of PFS events are shown in Figure 2A . Similar to power calculations for investigator-assessed PFS, the conditional and predictive powers for centrally reviewed PFS fluctuated over time. Conditional power was generally >70% and predictive power was typically >60% for centrally reviewed PFS. The corresponding HRs for centrally reviewed PFS improved as the number of PFS events increased ( Figure 2B ), resulting in a statistically significant improvement in centrally reviewed PFS favouring nintedanib-pemetrexed over placebo-pemetrexed (HR 0.83, 95% CI 0.70-0.99, P ¼ 0.0435, median PFS: 4.4 versus 3.6 months) at the time of the primary analysis (9 July 2012).
Retrospective analysis using alternative futility rules Table 2 shows the outcomes of using an alternative method for futility assessment, with various different assumed HRs. As shown in Table 2 , using the Hwang et al. [25] spending function and an assumed HR of 0.75, as per the original power calculations, 14.6% of studies would have been wrongly stopped for futility.
Discussion
The LUME-Lung 2 study showed a statistically significant improvement in the primary endpoint, PFS by central review, at the time of the final analysis, even though the study was stopped prematurely following a pre-planned futility analysis of investigatorassessed PFS [21] . Thus, the futility calculation on which the DMC based its decision to stop the study was an inadequate estimate of the final results. Our retrospective analysis indicates that the conditional power only dropped below the threshold predefined by the DMC charter (namely, a conditional power below 20%) at the time of the futility analysis for investigator-assessed PFS and that the conditional power for PFS by central review did not fall below the 20% threshold at any point during the study. Had the DMC analysis been carried out at another time point, or had centrally reviewed data been used, the outcome of the futility analysis might have been different. It should be noted that in this study, the treatment effect was moderate though still clinically relevant (the final HR was 0.83). Studies in which the treatment effect is moderate may be more vulnerable to similar pitfalls that were encountered in this study; larger treatment effects are more likely to be apparent early on in the study, and these studies are unlikely to have low conditional power. However, some general lessons can be learned. One potential explanation for the discrepancy between the findings of the futility and final analysis is the use of different assessors. LUME-Lung 2 used independent, centrally reviewed PFS for the primary efficacy outcome-the most robust and unbiased method of assessment recommended by both RECIST and the World Health Organization [27] . Futility analyses, however, were based on investigator-assessed PFS and, although overall concordance between investigator-assessed and centrally reviewed PFS was 80% at the time of the primary analysis (see sup plementary Table S1 , available at Annals of Oncology online), there was some discordance. Results from the primary analysis reported here showed that PFS was about 1 month longer with investigator assessment than with centrally reviewed PFS for both nintedanib (5.3 versus 4.4 months) and placebo (4.3 versus 3.6 months) and was longer than shown in previous analyses [28] . Although this 1-month difference may be of questionable Retrospective analysis showed that the conditional and predictive powers for PFS based on investigator assessment on 14 March 2011 (i.e. the cut-off date for the DMC analysis, shown in red) were 13.3% and 21.6%, respectively. The conditional and predictive powers for PFS based on investigator assessment when 50% of events had occurred (the actual timing of the planned futility analysis, shown in red) were 21.0% and 27.9%, respectively. CI, confidence interval; DMC, Data Monitoring Committee; PFS, progression-free survival.
clinical relevance, the HR for centrally reviewed PFS was also superior to the HR for investigator-assessed PFS (17.8% versus 9.4% reduction in risk of a PFS event). A potential explanation for this difference is that the central independent review classified twice as many placebo-treated patients than nintedanib-treated patients (18% versus 9%) as having progressed earlier (<9 weeks) than the investigator's assessment. This issue is inherent to the use of endpoints such as PFS, which are based on tumour response and, unlike OS, are difficult to assess, are subject to measurement error and bias, and may also be influenced by frequency of assessment [29, 30] . Of note, median follow-up times were similar between treatment groups, indicating that this was not a source of bias. Our retrospective review showed that there were no errors of inference. It was surprising that the conditional and predictive powers fluctuated as much as they did over time. Reasons behind this fluctuation remain unclear and the question of whether this variability could be expected remains unanswered. It is possible that confounding factors contributed to this variability, such as missing information on stratification factors at the time of the interim analysis or imbalances in recruitment at the interim analysis that resulted in an unrepresentative patient sample. Random chance may also have contributed to the observed variability. Whatever the underlying causes, the extent of variability meant that although there were no errors of inference at the time of the futility analysis, it was a mistake to think that the chance of the inference changing would be small if the study were to continue. However, the decision to halt the study was made taking not only statistical, but also ethical, clinical and practical considerations into account.
Although it is not possible to remove all risk that a futility analysis may turn out to be inadequate, the findings of this analysis Retrospective conditional and predictive powers (A) and hazard ratios and 95% confidence intervals (B) for centrally reviewed PFS over time. Dates represent the timing of the last progression event. Analyses were conducted following database lock on 9 July 2012 (the primary PFS result is shown in red). Conditional and predictive powers after 40% of PFS events had occurred were 23.0% and 31.0%, respectively, and increased to 82.5% and 73.0%, respectively, after 50% of PFS events. CI, confidence interval; PFS, progression-free survival.
raise some important considerations for the design of futility evaluations. Firstly, careful consideration should be given to the pre-specified criteria for futility [6] . Criteria chosen should give consideration to the choice of control treatment and the size of the improvement over control that will represent a clinical benefit. For an add-on study design, such as LUME-Lung 2, it has been suggested that a conditional power threshold of 20% represents an aggressive stopping boundary when 50% of events have occurred. A retrospective analysis of futility criteria applied to 10 randomized cancer studies recommended a lower conditional power threshold (15%) to reduce the likelihood of erroneous triggering of futility [31] . Of note, LUME-Lung 2 would still have been stopped for futility with this lower criterion. In the retrospective analysis, one of five evaluated studies showing a statistically significant treatment effect at study end would have been stopped erroneously for futility based on this threshold [31] . Therefore, the conservative 10% threshold after 50% of the events for the primary PFS analysis [32] would have been needed to prevent early termination of LUME-Lung 2. It is difficult to comment on how our conditional power assumptions compare with other studies in lung cancer that have been stopped for futility, as previous studies [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 33] either did not use conditional power in the futility assessment or provided insufficient details on the conditional power thresholds used. Selection of the appropriate conditional power threshold for a trial must be made by the DMC based on the balance between loss of power, resource saving, the patient population and patient safety; no one threshold would be appropriate for all studies. When recommending a threshold, the criterion for which it applies must be stated. For instance, a conditional power threshold has no clear meaning if the hypothesis for which the calculation was made is not specified. Furthermore, it has been argued that thresholds themselves are not really appealing and that the loss of power by making use of a futility analysis is more important [34] . If a futility analysis has established that the required threshold for conditional power has not been met and there is a possibility of early termination for futility, the DMC may wish to evaluate the degree and direction of drift (difference to the expected result) associated with the hypothesis being tested, and more importantly with the alternative hypothesis. This could, for example, provide useful insight and inform the decision about whether or not to continue the study.
Should DMC decisions to stop a trial for futility be based on more than one futility assessment? Futility analyses are frequently conducted after 50% of the information from a trial has been accrued, as in LUME-Lung 2. Although multiple interim analyses throughout a trial are possible [34] , early monitoring for lack of benefit can be unreliable as insufficient events may have been observed to produce a reliable effect. A further consideration is that, if a particular data set is analysed repeatedly, it is more likely that a significant result will occur based on chance. Therefore, the best approach may be to conduct additional interim evaluations if the initial futility assessment does not indicate a clear negative effect of the new treatment and especially in situations where the data on which futility assessment was based may not be clean.
Successive interim analyses would strengthen any decision to terminate. In light of the reported discordance between central and investigator review, we would agree with the recommendations to base futility decisions on more than one endpoint [31, 35] . Alternatively, when a surrogate endpoint is used at the interim analysis, this should be explicitly accounted for in any decisions to terminate.
The use of conditional power is only one methodology to assess futility, although many methods are subject to the same limitations associated with conditional power calculations; namely, analyses involve use of observed data (which are not clean) and an assumption regarding the distribution of future, unobserved data in each treatment group [36] . As such, use of alternative methods may still have resulted in the LUME-Lung 2 trial being stopped erroneously for futility. Indeed, simulations using a group sequential design with a non-binding stopping rule for futility, such as that of Hwang et al., still resulted in a 15% change, and the trial would have been wrongly stopped for futility using the original treatment effect assumptions used in LUME-Lung 2; the chances of erroneously stopping was increased using alternative HR assumptions from later in the trial. A DMC decision to stop a trial for futility will always be based on a balance of probability, alongside consideration of other factors. It is important for the DMC to have clear guidelines from the study sponsor from the outset. Although the futility analysis in LUME-Lung 2 was not binding, the sponsor decided to act in accordance with the DMC's recommendation and stop the study. The details of the statistical considerations that contributed to this decision have been discussed above. However, a number of other factors were also relevant to the decision, and are important to consider alongside the statistical aspects of the study design. They included, but were not limited to: evaluation of whether the study still had the potential to achieve its primary endpoint based on available clinical evidence; ethical consideration of whether new study participants should be randomized to receive study treatment; due consideration of the expertise within the DMC, and whether or not it would be appropriate to overrule their recommendation; and practical evaluation of the resources required to continue to accrue patients into the study (e.g. time and effort from study investigators and patients, and the potential need to open new study sites to complete accrual). Although it might be expected that stopping a study early would reduce the resources and cost required for completing it, this consideration is less relevant in cases such as this, when a large number of sites are already open and patients remain on study treatment. However, in other cases, futility analyses may provide valuable insights that can be used to adapt the design of the study in question, of other ongoing studies, or to make more efficient use of resources. It would be interesting to see more published research on this matter.
Conclusions
Careful consideration should be given to the decision to terminate a study for futility, as futility calculations do not always get it right and can represent an inadequate estimate of the final trial results. Given the consequences of early termination, it may be reasonable to evaluate how the termination criteria behaved over time. Decisions to terminate a study should always be made after due consideration of all aspects of the study, including toxicity and other endpoints.
